Tropicamide/phenylephrine, sold under the brand name Mydcombi is a fixed dose combination of tropicamide and phenylephrine used to dilate the eyes (mydriasis).[1] It contains, tropicamide, an anticholinergic, and phenylephrine, as the hydrochloride, an alpha-1 adrenergic receptor agonist.[1] It is sprayed into the eyes.[1]
| Combination of | |
|---|---|
| Tropicamide | Anticholinergic |
| Phenylephrine | Alpha-1 adrenergic receptor agonist |
| Clinical data | |
| Trade names | Mydcombi |
| Routes of administration | Topical, ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
It was approved for medical use in the United States in May 2023.[2][3]
Medical uses edit
Tropicamide/phenylephrine is used for the short-term dilation of the pupils.[1]
References edit
- ^ a b c d e https://mydcombi.com/wp-content/uploads/2023/05/MydCombi-PI-05072023.pdf
- ^ "Mydcombi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 8 May 2023.
- ^ "Eyenovia Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet Device Platform". Eyenovia. 8 May 2023. Retrieved 8 May 2023.
External links edit
- Clinical trial number NCT03751631 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-1)" at ClinicalTrials.gov
- Clinical trial number NCT03751098 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-2)" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |